Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
- PMID: 28405170
- PMCID: PMC5378445
- DOI: 10.2147/PGPM.S125452
Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
Abstract
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because their use may lead to excellent cure rates with fewer side effects. In Latin America, the high prevalence of HCV genotype 1 infection and the significant association of Native American ancestry with risk predictive single-nucleotide polymorphisms (SNPs) in IFNL4 and ITPA genes highlight the need to implement new treatment regimens in these populations. However, the universal accessibility to DAAs is still not a reality in the region as their high cost is one of the major, although not the only, limiting factors for their broad implementation. Therefore, under these circumstances, could the assessment of host genetic markers be a useful tool to prioritize DAA treatment until global access to these new drugs can be achieved? This review will summarize the scientific evidences and the potential implications of HCV pharmacogenomics in this rapidly evolving era of anti-HCV drug development.
Keywords: DAAs; Latin America; PEG-IFN/RBV; hepatitis C virus; pharmacogenomics.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures






Similar articles
-
Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.BMC Infect Dis. 2014;14 Suppl 5(Suppl 5):S3. doi: 10.1186/1471-2334-14-S5-S3. Epub 2014 Sep 5. BMC Infect Dis. 2014. PMID: 25236374 Free PMC article.
-
All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.Curr Mol Med. 2018;18(7):409-435. doi: 10.2174/1566524019666190104110439. Curr Mol Med. 2018. PMID: 30608042 Review.
-
Role of IL28B for chronic hepatitis C treatment toward personalized medicine.J Gastroenterol Hepatol. 2014 Feb;29(2):241-9. doi: 10.1111/jgh.12475. J Gastroenterol Hepatol. 2014. PMID: 24325405 Review.
-
Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.World J Gastroenterol. 2015 Oct 14;21(38):10749-59. doi: 10.3748/wjg.v21.i38.10749. World J Gastroenterol. 2015. PMID: 26478667 Free PMC article. Review.
-
The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.Open Forum Infect Dis. 2015 Nov 12;2(4):ofv168. doi: 10.1093/ofid/ofv168. eCollection 2015 Dec. Open Forum Infect Dis. 2015. PMID: 26697509 Free PMC article.
Cited by
-
Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.Viruses. 2018 Dec 21;11(1):3. doi: 10.3390/v11010003. Viruses. 2018. PMID: 30577623 Free PMC article.
-
Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.Dis Markers. 2018 Aug 14;2018:2514901. doi: 10.1155/2018/2514901. eCollection 2018. Dis Markers. 2018. PMID: 30186532 Free PMC article.
-
The Ethics of Precision Rationing: Human Genetics and the Need for Debate on Stratifying Access to Medication.Public Health Genomics. 2020;23(3-4):149-154. doi: 10.1159/000508141. Epub 2020 Jun 9. Public Health Genomics. 2020. PMID: 32516789 Free PMC article.
References
-
- Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J Infect. 2014;68(1):1–20. - PubMed
-
- Suppiah V, Moldovan M, Ahlenstiel G, et al. Interleukin 28B is associated with response to Hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(1):1100–1104. - PubMed
-
- Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of Interleukin 28B with response to interferon alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–1109. - PubMed
-
- Ge D, Fellay J, Thompson AJ, et al. Genetic variation in interleukin 28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. - PubMed
-
- Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in interleukin 28B is associated with chronic hepatitis C and treatment failure: genome-wide association study. Gastroenterology. 2010;138(4):1338–1345. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous